# Assessment of Airway Function in Asthma

Mark Mottershaw




#### Introduction

- Guidelines
  - BTS 2016
  - "Confirmation of asthma hinges on demonstration of airflow variability over short periods."
- Understand normal
- Interpret deviations from normal
- Assess results of standard interventions
- Awareness of alternatives


## **Expressing Normality**

- Percent Predicted
- Lower limit of normal (LLN)
- Standard Residual

#### Normal Distribution



#### Normal Distribution(s)




#### Standard Residual

- The number of standard deviations (Z scores) from the population mean.
- Applicable to all lung function indices

Standard Residual (SR)	Severity
> -1.65	Normal
- 1.65 to -2.50	Mild
- 2.50 to - 3.50	Moderate
< -3.50	Severe

# Airway Indices


- PEF
- FEV<sub>1</sub>
- FEV1 Ratio, FEV1/FVC
- "Mid expiratory flows"



#### The FEV1

- Predominance and Pre-eminence in medical education
- Misleading
  - Reduced in restriction
  - Often "normal" with hyperinflation
- Still recommended to determine severity in COPD
  - Equally misleading
- Learn to hate it

# The FEV1




#### The FEV1

- Predominance and Pre-eminence in medical education
- Misleading
  - Reduced in restriction
  - Often "normal" with hyperinflation
- Still recommended to determine severity in COPD
  - Equally misleading

# Severity

Post Bronchodilat or FEV <sub>1</sub> Ratio	FEV <sub>1</sub> % Predicted	NICE Clinical Guideline GOLD 2008 (2010)		ATS/ERS 2004	Standard Residual (SR)
> 0.7	> 80%	Normal	Normal	Normal	> - 1.65
< 0.7	≥ 80%	Stage 1 – Mild*	Stage 1 – Mild	Mild	- 1.65 to - 2.50
< 0.7	50 – 79%	Stage 2 – Moderate	Stage 2 – Moderate	Moderate	- 2.50 to - 3.50
< 0.7	30 – 49%	Stage 3 – Severe	Stage 3 – Severe	Severe	< -3.50
< 0.7	< 30%	Stage 4 – Very Severe**	Stage 4 – Very Severe**	Very Severe	-

#### Severity Interpretation



- FEV1 2.57 (69% pred)
- FVC 3.73 (81% pred)
- Ratio 69% (pred is 78%)
- Moderate obstruction
- FEV1 3.00 (81% pred)
- FVC 6.22 (135% pred)
- Ratio 48% (pred is 78%)
- Mild Obstruction

#### The FEV1 Ratio

- Primary index of airflow limitation in spirometry
- Normal Value?

#### **FEV1** Ratio

- 80 year old male, height 1.78m
- Reference FEV1 Ratio 71%
  - LLN ~ 60%

Parameter	Value	Reference Value	% Predicted	Standard Residual
FEV1 (L)	2.16	2.61	83	-0.89
FVC (L)	3.62	3.62	100	-0.01
FEV1 Ratio	60	71	84	-1.63

#### **FEV1** Ratio

- 18 year old female, height 1.78m
- Reference FEV1 Ratio 86%
  - LLN 75%

Parameter	Value	Reference Value	% Predicted	Standard Residual
FEV1(L)	2.73	3.98	69	-3.29
FVC (L)	4.53	4.53	100	0.00
FEV1 Ratio	60	86	70	-3.90


#### Severity Interpretation Using FEV1 Ratio

7.17

- FEV1 2.57 (69% pred)
- FVC 3.73 (81% pred)
- Ratio 69% (pred is 78%)
- Moderate obstruction
- FEV1 3.00 (81% pred)
- FVC 6.22 (135% pred)
- Ratio 48% (pred is 78%)
- Mild Obstruction

SR = <u>Measured – Predicted</u> Residual Standard Deviation (7.17)

$$48 - 78 = -4.18$$
 (Severe Obstruction)




# Spirometry Interpretation

Spirometry	FVC	FEV <sub>1</sub> Ratio
Normal	> LLN (⇔)	> LLN (⇔)
Obstructive	> LLN (⇔)	< LLN / SR (♥)
? Restrictive	< LLN ( <b>↓</b> )	> LLN (⇔)
Combined	< LLN ( <b>♣</b> )	< LLN ( <b>♣</b> )

## Mid Expiratory Flows

- Smaller airway function
- Different units
- Wider variation
- Interpret cautiously




#### PEF

- Variability and diurnal variation
- Variability > 10% suggestive of abnormality and suboptimal control with BD measurements

Highest PEF – Lowest PEF x 100 Mean of highest+ Lowest PEF

Visual diurnal variation


#### PEF diurnal variation




#### Reversibility

- Spirometry and change in FEV1 still considered gold standard for assessing reversibility
- 200 ml AND 12% Increase in FEV1


# Reversibility





		14:51		15:24		
unit	pred.	pre	%pred.	post	%pred.	post%pre
1 .	3.46	3.28	95	3.93	114	20
	3.01	2.08	69	3.23	107	55
%		60		82		37
%		63		82		29
l/min	411	320	78	511	124	60
l/s	6.03	2.69	44	6.67	110	148
l/s	5.23	1.76	34	4.56	87	158
l/s	2.05	0.54	26	1.33	65	146
l/min	235	74	31	190	81	157
	   %   %  /min  /s  /s	I 3.46 I 3.01 % % I/min 411 I/s 6.03 I/s 5.23 I/s 2.05	unit pred. pre 1 3.46 3.28 1 3.01 2.08 % 60 % 63 I/min 411 320 I/s 6.03 2.69 I/s 5.23 1.76 I/s 2.05 0.54	unit pred. pre %pred.    3.46   3.28   95     3.01   2.08   69     60     63    /min   411   320   78    /s   6.03   2.69   44    /s   5.23   1.76   34    /s   2.05   0.54   26	unit         pred.         pre %pred.         post           I         3.46         3.28         95         3.93           I         3.01         2.08         69         3.23           %         60         82           %         63         82           I/min         411         320         78         511           I/s         6.03         2.69         44         6.67           I/s         5.23         1.76         34         4.56           I/s         2.05         0.54         26         1.33	unit         pred.         pre %pred.         post %pred.           I         3.46         3.28         95         3.93         114           I         3.01         2.08         69         3.23         107           %         60         82           %         63         82           I/min         411         320         78         511         124           I/s         6.03         2.69         44         6.67         110           I/s         5.23         1.76         34         4.56         87           I/s         2.05         0.54         26         1.33         65

# Reversibility




#### **Parameter**

FEV1 FVCex FEV1/FVC FEV1/IVC PEF MEF25 MEF80 MEF75


%Ref	
64%	
24%	
40%	
189%	
4%	
4%	
9%	
	39% 8% 4%

ı	Effort 1	
		%Ref
0	4,41	69%
	4,59	
	3.98	106%
	5.08	107%
	78	
	90	
	589	109%
	84	71%
	288	99%
	445	94%
*	0.08	
-	10.1	


- One of few indices where value greater than average suggests pathology
- May suggest airway disease with normal spirometry



Pressure change within box




Pressure change within box



Pressure change within box


PARAMETER	UNIT	PRED.	PRE	%PRED.	SR	POST	%PRED.	SR	POST%
FEV1	- 1	2.65	2.21	83	-1.16	2.18	82	-1.24	-1
FVCex	1	3.08	2.81	91	-0.63	2.68	87	-0.92	-4
FEV1/FVC	%		79			81			3
VC	1	3.05	2.67	88	-0.89	2.70	89	-0.83	1
FEV1/IVC	%		83			81			-2
PEF	I/min	383	345	90	-0.70	376	98	-0.14	9
FIV1	1	2.73	2.44	89		2.48	91		2
FVCin	-1	3.05	2.65	87	-0.96	2.66	87	-0.91	1
PIF	I/min	258	175	68	-1.51	223	86	-0.64	28




#### **Body Plethysmography**


#### **LUNG VOLUMES AND SUBDIVISIONS**


PARAMETER	UNIT	PRED.	PRE	%PRED.	SR	POST	%PRED.	SR	POST% PRE
TLC	1	4.57	3.75	82	-1.38	3.93	86	-1.08	5
RV	- 1	1.45	0.94	65	-1.45	1.18	81	-0.78	25
VC	1	3.05	2.67	88	-0.89	2.70	89	-0.83	1
TGV	- 1	2.55	1.65	65	-1.80	1.99	78	-1.13	20
TGV/TLC	%	51	44	86	-0.72	51	99	-0.05	15
RV/TLC	%	32	25	79	-1.16	30	94	-0.33	19
RESISTANCE									
	Pa/(I/s) kPa*s	0.30 0.77	0.95 1.58	318 206		0.25 0.49	82 64		-74 -69






Abbreviation	Parameter
$R_5$	Resistance (5 Hz)
R <sub>20</sub>	Resistance (20 Hz)
$R_5 - R_{20}$	Resistance (5–20 Hz)
$X_5$	Reactance (5 Hz)
Ax	Reactance area
F <sub>res</sub>	Resonant frequency








#### Other tests

- Challenge test
- Lung Clearance Index (LCI)
  - Time to washout inert gas
  - Index of obstruction
  - ? Different patterns with different airway involvement
- Capnography
  - Altered waveforms in normal, asthma and COPD

# Challenge Test

PC/PD20



#### Other tests

- Challenge testing
- Lung Clearance Index (LCI)
  - Time to washout inert gas
  - Index of obstruction
  - ? Different patterns with different airway involvement
- Capnography
  - Altered waveforms in normal, asthma and COPD

#### Conclusions

- Assessment of airway function and changes over short periods important for confirmation of asthma diagnosis
- Accurate assessment depends on understanding normal values, expressions of normality and interpretative strategies
- Spirometry is still gold standard for assessing changes in airway function
- Tidal breathing assessment becoming more clinically available with complementary utility.